SCHEMBL1230281

SCHEMBL1230281

CCCC[O-].CC[O-].CC[O-].CC[O-].[Ti+4]

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.43
LMNA P02545 1/20 0.43
THRB P10828 1/20 0.40
CES1 P23141 6/20 0.35
CES2 O00748 5/20 0.35
ALDH1A1 P00352 3/20 0.33
TDP1 Q9NUW8 1/20 0.33
SLC22A1 O15245 2/20 0.32
SLC22A2 O15244 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
LSS P48449 1/20 0.30
CA1 P00915 1/20 0.30
DNM1 Q05193 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32664559 1.00 TSHR (0.43) TSHRLMNATHRBCES1CES2
SCHEMBL1230027 1.00 TSHR (0.43) TSHRLMNATHRBCES1CES2
SCHEMBL4425224 0.96 TSHR (0.40) TSHRLMNATHRBCES1CES2
SCHEMBL5667021 0.96 TSHR (0.40) TSHRLMNATHRBCES1CES2
SCHEMBL7092821 0.96 TSHR (0.40) TSHRLMNATHRBCES1CES2
SCHEMBL29398848 0.96 TSHR (0.46) TSHRLMNATHRBCES1CES2
SCHEMBL16432 0.96 TSHR (0.46) TSHRLMNATHRBCES1CES2
Hydrochloric Acid SCHEMBL1034009 0.92
Potassium Ion SCHEMBL17085518 0.92 TSHR (0.43) TSHRLMNATHRBCES1CES2
SCHEMBL1229816 0.92 TSHR (0.43) TSHRLMNATHRBCES1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12623999-B2 Carbamate production method, carbamate ester production method, and urea derivative production method NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2026-05-12 US disclosed
EP-4692247-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2026-02-11 EP disclosed
US-20260022211-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2026-01-22 US disclosed
US-20240392175-A1 THERMALLY CONDUCTIVE SILICONE COMPOSITION AND METHOD FOR PRODUCING GAP FILLER USING SAID COMPOSITION WACKER CHEMIE AG (DE) 2024-11-28 US disclosed
EP-4410899-A1 THERMALLY CONDUCTIVE SILICONE COMPOSITION AND METHOD FOR PRODUCING GAP FILLER USING SAID COMPOSITION Wacker Chemie AG (DE) 2024-08-07 EP disclosed
CN-114621372-B Ultra-high molecular weight ethylene homopolymers and process for preparing the same 中国石油化工股份有限公司 2024-04-09 CN disclosed
CN-114507310-B Ultra-high molecular weight ethylene copolymer and preparation method thereof 中国石油化工股份有限公司 2024-04-02 CN disclosed
CN-110964136-B Composite carrier supported non-metallocene catalyst, preparation method and application thereof 中国石油化工股份有限公司 2023-08-04 CN disclosed
CN-110964132-B Composite carrier segmented in-situ supported non-metallocene catalyst and preparation method thereof 中国石油化工股份有限公司 2023-08-04 CN disclosed
CN-110964140-B In-situ supported non-metallocene catalyst, preparation method and application thereof 中国石油化工股份有限公司 2023-08-04 CN disclosed
US-20080194773-A1 Polysiloxane from silanetriol group, a titanium, aluminum or a zirconium catalyst, and a low molecular weight compound containing a hydrolyzable silicon group; sealants, adhesives KANEKA CORPORATION (JP) 2008-08-14 US disclosed
US-20080076878-A1 Organic polymer having a silane tiol group, a titanium, aluminum or a zirconium catalyst, and a low molecular weight compound containing a hydrolyzable silicon group; sealants, adhesives KANEKA CORPORATION (JP) 2008-03-27 US disclosed
US-20080033087-A1 Polyoxyalkylene glycol or a methacrylate polymer containing a crosslinkable silicon group; a titaniuim chelate of an alkyl acetoacetoate or derivative; and an amide wax thickener; highly curable KANEKA CORPORATION (JP) 2008-02-07 US disclosed
US-20070219299-A1 Organic polymer having a silane tiol group, a titanium, aluminum or a zirconium catalyst, and a low molecular weight compound containing a hydrolyzable silicon group; sealants, adhesives KANEKA CORPORATION 2007-09-20 US disclosed
EP-1752496-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2007-02-14 EP disclosed
EP-1749857-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2007-02-07 EP disclosed
EP-1749858-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2007-02-07 EP disclosed
EP-1746134-A1 CURABLE COMPOSITION WITH IMPROVED CURABILITY AND ADHESIVENESS Kaneka Corporation (JP) 2007-01-24 EP disclosed
EP-1746133-A1 CURABLE COMPOSITION IMPROVED IN ADHESIVENESS Kaneka Corporation (JP) 2007-01-24 EP disclosed
EP-1746135-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12623999-B2 Carbamate production method, carbamate ester production method, and urea derivative production method CPS1, CA2, CHRM2 TSHR 525/4885LMNA 3572/4885THRB 140/4885
US-20260022211-A1 CURABLE COMPOSITION H1-4, H1-0, H1-2 TSHR 2520/4885LMNA 1462/4885THRB 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.